JP2008540634A - 新規オキサジアゾール誘導体及び代謝型グルタミン酸受容体の正のアロステリック調節因子としての当該誘導体の使用 - Google Patents

新規オキサジアゾール誘導体及び代謝型グルタミン酸受容体の正のアロステリック調節因子としての当該誘導体の使用 Download PDF

Info

Publication number
JP2008540634A
JP2008540634A JP2008511819A JP2008511819A JP2008540634A JP 2008540634 A JP2008540634 A JP 2008540634A JP 2008511819 A JP2008511819 A JP 2008511819A JP 2008511819 A JP2008511819 A JP 2008511819A JP 2008540634 A JP2008540634 A JP 2008540634A
Authority
JP
Japan
Prior art keywords
phenyl
fluoro
oxadiazol
methanone
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008511819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540634A5 (enExample
Inventor
ブガダ，ピエルジュリアーノ
ガグリアルディ，ステファニア
ポール，エマニュエル ル
ムテル，バンサン
パロンビ，ジョバンニ
ロシェル，ジャン−フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Addex Pharmaceuticals SA
Original Assignee
Addex Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharmaceuticals SA filed Critical Addex Pharmaceuticals SA
Publication of JP2008540634A publication Critical patent/JP2008540634A/ja
Publication of JP2008540634A5 publication Critical patent/JP2008540634A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008511819A 2005-05-18 2006-05-17 新規オキサジアゾール誘導体及び代謝型グルタミン酸受容体の正のアロステリック調節因子としての当該誘導体の使用 Pending JP2008540634A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0510142.3A GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1
PCT/IB2006/001674 WO2006123249A2 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Publications (2)

Publication Number Publication Date
JP2008540634A true JP2008540634A (ja) 2008-11-20
JP2008540634A5 JP2008540634A5 (enExample) 2009-07-02

Family

ID=34708380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511819A Pending JP2008540634A (ja) 2005-05-18 2006-05-17 新規オキサジアゾール誘導体及び代謝型グルタミン酸受容体の正のアロステリック調節因子としての当該誘導体の使用

Country Status (17)

Country Link
US (1) US20090197897A1 (enExample)
EP (1) EP1896463A2 (enExample)
JP (1) JP2008540634A (enExample)
KR (1) KR20080031676A (enExample)
CN (1) CN101218232B (enExample)
AU (1) AU2006248649B2 (enExample)
BR (1) BRPI0610681A2 (enExample)
CA (1) CA2608012A1 (enExample)
EA (1) EA015263B1 (enExample)
GB (1) GB0510142D0 (enExample)
IL (1) IL187190A0 (enExample)
MX (1) MX2007014405A (enExample)
NO (1) NO20076479L (enExample)
NZ (1) NZ564253A (enExample)
UA (1) UA92496C2 (enExample)
WO (1) WO2006123249A2 (enExample)
ZA (1) ZA200710277B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体
JP2012524798A (ja) * 2009-04-23 2012-10-18 メルク・シャープ・エンド・ドーム・コーポレイション ２−アルキルピペリジンｍｇｌｕｒ５受容体モジュレーター
WO2016153023A1 (ja) * 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123255A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2009099177A1 (ja) * 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
ES2610362T3 (es) 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
WO2022056042A1 (en) * 2020-09-09 2022-03-17 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
IL291418B2 (en) 2022-03-16 2024-05-01 Anima Biotech Inc Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment
CN117756793A (zh) * 2022-12-16 2024-03-26 四川大学 1,2,4-杂二唑衍生物及其用途

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258456A (ja) * 1987-03-31 1988-10-25 アクチエゼルスカブ・フエロサン ４−フエニルピペリジン化合物、その製造方法及びその使用方法
WO2000020414A1 (en) * 1998-10-02 2000-04-13 Combichem, Inc. Piperidyloxadiazoles as dopamine receptor antagonists
JP2000505089A (ja) * 1996-10-18 2000-04-25 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト オキサジアゾール、それらの調製方法及び医薬組成物としてのそれらの使用
WO2001054507A1 (en) * 2000-01-28 2001-08-02 Akkadix Corporation Methods for killing nematodes and nematode eggs using oxadiazole and oxaimidazole compounds
JP2002526528A (ja) * 1998-10-07 2002-08-20 ジョージタウン ユニヴァーシティー 単量体およびニ量体の複素環、ならびにその治療的使用
WO2003084948A1 (en) * 2002-03-14 2003-10-16 Eisai Co., Ltd. Nitrogenous heterocyclic compound and medicine thereof
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2005501026A (ja) * 2001-06-28 2005-01-13 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 化合物
JP2005510506A (ja) * 2001-09-21 2005-04-21 三菱ウェルファーマ株式会社 ３−置換−４−ピリミドン誘導体
JP2005510472A (ja) * 2001-09-21 2005-04-21 三菱ウェルファーマ株式会社 ３−置換−４−ピリミドン誘導体
JP2007510713A (ja) * 2003-11-06 2007-04-26 アデックス ファーマシューティカルズ ソシエテ アノニム 代謝型グルタミン酸受容体のアロステリック調節因子
JP2008514587A (ja) * 2004-09-29 2008-05-08 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としての６−ピリジニル−４−ピリミドン誘導体
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5891600A (en) * 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
ATE307129T1 (de) * 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
PL369598A1 (en) * 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2006503827A (ja) 2002-09-06 2006-02-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アレルギー性鼻炎治療用薬剤を製造する目的でインドリル誘導体を用いる使用
AU2004226450A1 (en) 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
SG149900A1 (en) * 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006123255A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258456A (ja) * 1987-03-31 1988-10-25 アクチエゼルスカブ・フエロサン ４−フエニルピペリジン化合物、その製造方法及びその使用方法
JP2000505089A (ja) * 1996-10-18 2000-04-25 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト オキサジアゾール、それらの調製方法及び医薬組成物としてのそれらの使用
WO2000020414A1 (en) * 1998-10-02 2000-04-13 Combichem, Inc. Piperidyloxadiazoles as dopamine receptor antagonists
JP2002526528A (ja) * 1998-10-07 2002-08-20 ジョージタウン ユニヴァーシティー 単量体およびニ量体の複素環、ならびにその治療的使用
WO2001054507A1 (en) * 2000-01-28 2001-08-02 Akkadix Corporation Methods for killing nematodes and nematode eggs using oxadiazole and oxaimidazole compounds
JP2005501026A (ja) * 2001-06-28 2005-01-13 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 化合物
JP2005510506A (ja) * 2001-09-21 2005-04-21 三菱ウェルファーマ株式会社 ３−置換−４−ピリミドン誘導体
JP2005510472A (ja) * 2001-09-21 2005-04-21 三菱ウェルファーマ株式会社 ３−置換−４−ピリミドン誘導体
WO2003084948A1 (en) * 2002-03-14 2003-10-16 Eisai Co., Ltd. Nitrogenous heterocyclic compound and medicine thereof
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2007510713A (ja) * 2003-11-06 2007-04-26 アデックス ファーマシューティカルズ ソシエテ アノニム 代謝型グルタミン酸受容体のアロステリック調節因子
JP2008514587A (ja) * 2004-09-29 2008-05-08 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としての６−ピリジニル−４−ピリミドン誘導体
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"INTERCHIM INTERMEDIATES", INTERCHIM, JPN5008006303, 18 January 2005 (2005-01-18), FR, ISSN: 0002105585 *
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 9, JPN6011067473, 2001, pages 3113 - 3122, ISSN: 0002105579 *
COMGENEX PRODUCT LIST, JPN5008006302, 15 April 2005 (2005-04-15), US, ISSN: 0002105584 *
DATABASE ZREGISTRY [ONLINE], JPN5008006298, 23 January 2001 (2001-01-23), US, ISSN: 0002105580 *
DATABASE ZREGISTRY [ONLINE], JPN5008006299, 23 January 2001 (2001-01-23), US, ISSN: 0002105581 *
DATABASE ZREGISTRY [ONLINE], JPN5008006300, 23 January 2001 (2001-01-23), US, ISSN: 0002105582 *
DATABASE ZREGISTRY [ONLINE], JPN5008006301, 23 January 2001 (2001-01-23), US, ISSN: 0002105583 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体
JP2012524798A (ja) * 2009-04-23 2012-10-18 メルク・シャープ・エンド・ドーム・コーポレイション ２−アルキルピペリジンｍｇｌｕｒ５受容体モジュレーター
WO2016153023A1 (ja) * 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬

Also Published As

Publication number Publication date
EA200702468A1 (ru) 2008-06-30
ZA200710277B (en) 2009-03-25
KR20080031676A (ko) 2008-04-10
IL187190A0 (en) 2008-02-09
EP1896463A2 (en) 2008-03-12
NZ564253A (en) 2011-04-29
CN101218232B (zh) 2012-06-27
MX2007014405A (es) 2008-04-21
AU2006248649B2 (en) 2012-04-26
UA92496C2 (ru) 2010-11-10
US20090197897A1 (en) 2009-08-06
BRPI0610681A2 (pt) 2010-07-20
WO2006123249A3 (en) 2007-02-08
CA2608012A1 (en) 2006-11-23
CN101218232A (zh) 2008-07-09
GB0510142D0 (en) 2005-06-22
AU2006248649A1 (en) 2006-11-23
WO2006123249A2 (en) 2006-11-23
NO20076479L (no) 2008-01-29
EA015263B1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
US20100004284A1 (en) Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
RU2360902C2 (ru) Аллостерические модуляторы метаботропных глутаматных рецепторов
AU2006248649B2 (en) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US20100081690A1 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
JP2008540637A (ja) 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体
JP2008540635A (ja) 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体
HK1128919B (en) Allosteric modulators of metabotropic glutamate receptors
HK1094204B (en) Allosteric modulators of metabotropic glutamate receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130305